Published in Clin Pharmacokinet on January 01, 2004
Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol (2005) 1.06
Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol (2013) 0.93
Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur J Clin Pharmacol (2005) 0.91
Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol (2007) 0.88
A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. J Clin Pharmacol (2011) 0.86
Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol (2010) 0.84
Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. Clin Pharmacokinet (2009) 0.83
Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol (2012) 0.82
Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. Br J Clin Pharmacol (2010) 0.82
High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. Int J Clin Pharmacol Ther (2013) 0.80
Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. Ther Drug Monit (2010) 0.78
Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients. Clin Pharmacokinet (2015) 0.77
Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients. Pediatr Nephrol (2008) 0.77
Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. Br J Clin Pharmacol (2014) 0.76
Clinical mycophenolic acid monitoring in liver transplant recipients. World J Gastroenterol (2014) 0.76
Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. Br J Clin Pharmacol (2012) 0.76
Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study. Clin Exp Immunol (2014) 0.75
Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. Medicine (Baltimore) (2017) 0.75
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98
Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med (2008) 3.85
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology (2011) 3.81
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA (2012) 2.56
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47
Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res (2004) 2.41
Measurement of the integral refractive index and dynamic cell morphometry of living cells with digital holographic microscopy. Opt Express (2005) 2.40
Cell refractive index tomography by digital holographic microscopy. Opt Lett (2006) 2.19
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology (2009) 2.00
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
Living specimen tomography by digital holographic microscopy: morphometry of testate amoeba. Opt Express (2006) 1.94
Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant (2005) 1.82
Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum (2010) 1.75
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation (2016) 1.68
Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit (2009) 1.68
Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychother Psychosom (2014) 1.64
Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology (2008) 1.62
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther (2009) 1.58
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol (2014) 1.56
Simultaneous cell morphometry and refractive index measurement with dual-wavelength digital holographic microscopy and dye-enhanced dispersion of perfusion medium. Opt Lett (2008) 1.53
Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol (2013) 1.50
Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant (2004) 1.48
Automated segmentation of multiple red blood cells with digital holographic microscopy. J Biomed Opt (2013) 1.47
Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients. Hum Mutat (2012) 1.45
Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit (2008) 1.42
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther (2011) 1.37
Early cell death detection with digital holographic microscopy. PLoS One (2012) 1.35
In vivo endoscopic tissue diagnostics based on spectroscopic absorption, scattering, and phase function properties. J Biomed Opt (2003) 1.34
Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation (2008) 1.34
Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore) (2012) 1.31
Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit (2006) 1.30
Noninvasive characterization of the fission yeast cell cycle by monitoring dry mass with digital holographic microscopy. J Biomed Opt (2009) 1.26
Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm Res (2005) 1.25
Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant (2002) 1.23
Supernatant of Bifidobacterium breve induces dendritic cell maturation, activation, and survival through a Toll-like receptor 2 pathway. J Allergy Clin Immunol (2006) 1.22
Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet (2009) 1.21
Comparative study of human erythrocytes by digital holographic microscopy, confocal microscopy, and impedance volume analyzer. Cytometry A (2008) 1.20
An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit (2006) 1.17
Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos (2004) 1.15
A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation (2003) 1.13
Replacement kidney lipomatosis after renal transplantation. Transplantation (2005) 1.12
CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther (2006) 1.11
Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol (2012) 1.10
Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother (2010) 1.10
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther (2004) 1.10
A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis (2012) 1.10
In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos (2005) 1.08
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics (2008) 1.07
Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther (2005) 1.05
Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol (2007) 1.05
Numerical parametric lens for shifting, magnification, and complete aberration compensation in digital holographic microscopy. J Opt Soc Am A Opt Image Sci Vis (2006) 1.04
Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit (2005) 1.04
Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs (2010) 1.03
Quantification of interstitial fibrosis by image analysis on routine renal biopsy in patients receiving cyclosporine. Transplantation (2007) 1.02
Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol (2011) 1.02
Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int (2008) 1.01
Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy. Clin Transplant (2003) 1.01
TLR9 activation induces normal neutrophil responses in a child with IRAK-4 deficiency: involvement of the direct PI3K pathway. J Immunol (2007) 1.01
A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet (2005) 1.01
Determination of transmembrane water fluxes in neurons elicited by glutamate ionotropic receptors and by the cotransporters KCC2 and NKCC1: a digital holographic microscopy study. J Neurosci (2011) 1.00
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando) (2010) 1.00
Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol (2011) 1.00
Automatic procedure for aberration compensation in digital holographic microscopy and applications to specimen shape compensation. Appl Opt (2006) 0.99
Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients. Am J Transplant (2007) 0.99
Mechanisms underlying postmortem redistribution of drugs: a review. J Anal Toxicol (2003) 0.98
Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos (2010) 0.98
Cell morphology and intracellular ionic homeostasis explored with a multimodal approach combining epifluorescence and digital holographic microscopy. J Biophotonics (2010) 0.97
Submicrometer tomography of cells by multiple-wavelength digital holographic microscopy in reflection. Opt Lett (2009) 0.97
Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. Pharmacogenet Genomics (2012) 0.97
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet (2010) 0.96
The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. Pharm Res (2011) 0.96
Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit (2010) 0.96
Polarization microscopy by use of digital holography: application to optical-fiber birefringence measurements. Appl Opt (2005) 0.96
Label-free second-harmonic phase imaging of biological specimen by digital holographic microscopy. Opt Lett (2010) 0.95
Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. Inflamm Bowel Dis (2014) 0.95
Spatial analysis of erythrocyte membrane fluctuations by digital holographic microscopy. Blood Cells Mol Dis (2009) 0.94
An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. Ther Drug Monit (2010) 0.94
Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol (2002) 0.94
Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet (2009) 0.94
Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit (2004) 0.94
Pesticide contamination of workers in vineyards in France. J Expo Sci Environ Epidemiol (2006) 0.93
Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos (2006) 0.93
Total aberrations compensation in digital holographic microscopy with a reference conjugated hologram. Opt Express (2006) 0.93
Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit (2010) 0.93
Unexpected rate of severe leucopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients. Nephrol Dial Transplant (2006) 0.93
Supernatant from bifidobacterium differentially modulates transduction signaling pathways for biological functions of human dendritic cells. PLoS One (2008) 0.92
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res (2011) 0.92
Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. Transplantation (2006) 0.91
Screening of drugs and toxic compounds with liquid chromatography-linear ion trap tandem mass spectrometry. Clin Chem (2006) 0.91
mTOR inhibition: the learning curve in kidney transplantation. Transpl Int (2010) 0.91
Occupational exposure in ANCA-positive patients: a case-control study. Kidney Int (2005) 0.91
Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit (2004) 0.90
Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics (2007) 0.90
Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. Clin Pharmacokinet (2009) 0.90